Kolexia
Becouarn Yves Gastro-entérologie
Becouarn Yves
Gastro-entérologie
Institut Bergonié
Bordeaux, France
76 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Adénocarcinome Tumeurs du côlon Tumeurs du foie Tumeurs du rectum Carcinomes Tumeurs du péritoine Carcinome hépatocellulaire

Collaborateurs

Voir plus
Fonck-Frayssinet Marianne
Fonck-Frayssinet Marianne
Institut Bergonié, Bordeaux, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Bechade Dominique
Bechade Dominique
Institut Bergonié, Bordeaux, France
Evrard Serge
Evrard Serge
Institut Bergonié, Bordeaux, France

Industries

Voir plus
Sanofi
1 collaboration(s)
Dernière en 2019
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
IDEA: A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   27 septembre 2023
OMEGA: Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer
Essai Clinique (Institut Bergonié)   28 octobre 2022
SATURNE: A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   17 mars 2022
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases: Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases
Essai Clinique (Unicancer)   14 juin 2021
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer: Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
Essai Clinique (Unicancer)   05 mars 2021
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer: Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer
Essai Clinique (Unicancer)   25 février 2021
Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer: Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo
Essai Clinique (Unicancer)   15 février 2021
COCHISE: Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin
Essai Clinique (Institut Bergonié)   05 janvier 2021
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial
Essai Clinique (Unicancer)   13 novembre 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
Clinics and research in hepatology and gastroenterology   21 juin 2020